Abstract
The most influential analyses of the effectiveness of systemic adjuvant therapy of breast cancer are the 3 overview meta-analyses performed at Oxford and published in 19881, 19922, and 19983. These meta-analyses are a collaborative effort dependent on pooling of data by trialists of nearly all the randomized clinical trials of systemic adjuvant therapies. The major questions that were addressed by these Overview analyses were:
-
1)
Is systemic adjuvant therapy of breast cancer effective?
-
2)
Are there subsets of patients in whom given adjuvant therapies are particularly effective?
-
3)
How effective is the current adjuvant therapy?
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Anonymous. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer: an overview of 61 randomised trials among 28,896 women. Early Breast Cancer Trialists’ Collaborative Group. N Engl J Med 319: 1681–1692, 1988.
Anonymous. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Early Breast Cancer Trialists’ Collaborative Group. Lancet 339:1–15, 71–85, 1992.
Anonymous. Tamoxifen for early breast cancer: an overview of randomised. Early Breast Cancer Trialists’ Collaborative Group. Lancet 351: 1451–1467, 1998.
Ravdin PM. How can prognostic and predictive factors in breast cancer be used in a practical way today?. Recent Results in Cancer Research. 152: 8693, 1998.
Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 88: 1543–1549, 1996.
Fisher B, Dignam J, Bryant J, deCillis A, Wickerham DL, Wolmark N, et al. The worth of five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88: 1529–1542, 1996.
Anonymous. Ovarian ablation in early breast cancer: An overview of randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 348: 1189–1196, 1996.
Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM, Bowman D, Couture J, Dimitrov NV, Evans J, Farrar W, Kavanah M, Lickley HL, Margolese R, Paterson AHG, Robidoux A, Shibata H, Terz J. Endometrial cancer in tamoxifen treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B14. J Natl Cancer Inst 86: 527–537, 1994.
Love RR, Wiebe DA, Newcomb PA, et al. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women. Ann Intern Med 115: 860–864, 1991.
Henderson IC, Berry D, Demetri G. et al. Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node-positive primary breast cancer. Proc Am. Soc. Clinical Oncology 17: 390a, 1998.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2000 Springer Science+Business Media New York
About this chapter
Cite this chapter
Ravdin, P.M. (2000). Overview of Randomized Trials of Systemic Adjuvant Therapy. In: Gradishar, W.J., Wood, W.C. (eds) Advances in Breast Cancer Management. Cancer Treatment and Research, vol 103. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-3147-7_8
Download citation
DOI: https://doi.org/10.1007/978-1-4757-3147-7_8
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-3149-1
Online ISBN: 978-1-4757-3147-7
eBook Packages: Springer Book Archive